Research Snapshot: Genetic Score Shows Promise in Improving Leukemia Outcomes
By allowing chemotherapy regimens to be personalized, a genetic score holds promise for improving treatment results in patients with acute myeloid leukemia (AML) who have traditionally had poor outcomes, UF Health researchers have found.
The score could be used to identify patients more likely to have worse outcomes and optimize their treatment, according to the study of a large group of pediatric, adolescent and young adult patients with AML. The study was published on June 23 in JAMA Network Open.
“We showed the application of the score in one of the largest pediatric trials led by the Children’s Oncology Group and in adolescent and young adult patients treated across several trials led by Alliance,” said senior author Jatinder Lamba, Ph.D., a professor and dean in the UF College of Pharmacy and co-leader of the UF Health Cancer Center’s Cancer Targeting and Therapeutics research program. “Our results show the score is predictive of the outcome independent of the age groups, broadening its application.”
Read more about Research Snapshot: Genetic Score Shows Promise in Improving Leukemia Outcomes.Learn more about technologies discovered by Jatinder Lamba.